Search Results
Your search for Clifford A. Hudis, MD,Clifford A. Hudis, MD matches 242 pages
Showing 151 - 200Expert Point of View: Clifford A. Hudis, MD
These patients are mainly young men,” stated Clifford A. Hudis, MD, ASCO President, commenting on a cohort study of surveillance for stage I seminoma at a press conference held before the Annual Meeting. “For these selected patients, neither chemotherapy nor radiation therapy is necessary, sparing...
Oncologists Speak Out Against the High Cost of Cancer Drugs
That the United States spends twice as much on health care than other industrialized countries—about $2.8 trillion in 2012—without reaping appreciably better outcomes1 is not news. The topic has been dissected on the front pages of leading newspapers for years and was the subject of the entire...
Legislative Endorsement Update From ASCO
ASCO recently announced its endorsement of the Tobacco Tax Equity Act of 2014 (S. 194), which would close tax loopholes that allow tobacco companies to avoid the federal cigarette tax by making taxes on pipe tobacco equivalent to cigarette tobacco. “Raising tobacco taxes is one of the most...
ASCO Launches New Site to Seek Feedback from Cancer Community on Clinical Practice Guidelines
ASCO has launched a new wiki site to engage the cancer community in its clinical practice guideline development process. The new site will provide oncologists, practitioners and patients with an opportunity to provide feedback or submit evidence on individual published guidelines and can be...
Communicating the Promise Science Offers to Society
ASCO President Clifford Hudis, MD, FACP, will be serving during a particularly notable year: 2014, the Society’s 50th anniversary. This occasion brings with it much to reflect on, from the advances in the field of oncology to the growth of ASCO’s influence, but Dr. Hudis takes a moment to simply...
ASCO Releases Statement on the Impact of the Government Shutdown on Cancer Care
All nonessential government services were suspended at midnight on October 1, 2013, after Congress failed to reach a budget compromise to keep the government funded before the start of the new fiscal year beginning on October 1, 2013. ASCO issued a statement in response to the government shutdown...
Pathologic Complete Response as a Test Bed for Novel Therapies: Proceed—With Caution!
Pathologic complete response as assessed surgically after neoadjuvant treatment is being touted by some researchers as a stand-alone endpoint justifying early drug approval for breast cancer. They argue that it provides a more efficient means of testing the value of agents that might be useful in...
Zhe-Bin Liu, MD, PhD, of China Receives 2013 Long-Term International Fellowship in Breast Cancer
Zhe-Bin Liu, MD, PhD, of Shanghai Cancer Center, Fudan University, China, is the recipient of the 2013 Conquer Cancer Foundation of ASCO Long-Term International Fellowship (LIFe) in Breast Cancer, generously supported by The Breast Cancer Research Foundation. The LIFe provides early-career...
The Scientific Perils of Sequestration
We are just 7 months into the $1 trillion in automatic federal budget spending cuts known as sequestration, and the impact on scientists in all areas of research is already so great, some say its full effects may be irreversible. The ASCO Post recently interviewed ASCO President Clifford A. Hudis, ...
New Report Examines Trends in End-of-Life Care
Although fewer Medicare patients with cancer died in the hospital in 2010 than in the years 2003–2007, aggressive treatment continues at the end of life, according to a new report from the Dartmouth Atlas Project.1 The findings also show that a significant number of patients were likely to receive...
ASCO Announces Inaugural Class for Quality Training Program
For oncologists, continuous quality improvement is a key goal. We measure and assess the quality of care we deliver and constantly look for areas where we can do better,” said ASCO President Clifford A. Hudis, MD, FACP. “ASCO’s Quality Training Program will guide oncology care providers in...
Expert Point of View: Clifford Hudis, MD
Formal discussant Clifford Hudis, MD, ASCO President and Chief of the Breast Cancer Service at Memorial Sloan-Kettering Cancer Center in New York, commented that the findings were not surprising. “The results of TH3RESA nicely reflect the EMILIA trial and are consistent with those of anti-HER2...
IOM Report Illuminates U.S. Cancer Care Crisis and Offers Framework for Change
In September, the Institute of Medicine (IOM) of the National Academies issued its report, Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis,1 published more than a decade after its first study on the quality of cancer care in the United States. The authors of the...
ASCO Launches Formal Development of CancerLinQ™ System
ASCO recently announced that it has initiated development of the full CancerLinQ™ system, a groundbreaking health information technology (HIT) initiative to achieve higher-quality, higher-value cancer care with better outcomes for patients. The announcement was made at a White House Office of...
More Than 200 Practices Now QOPI® Certified for Delivering High-Quality Cancer Care
ASCO and its affiliate, the Quality Oncology Practice Initiative (QOPI®) Certification Program (QCP™), have announced that more than 200 practices have received certification. Since its start in 2010, the QOPI Certification Program has evaluated individual outpatient oncology practice performance...
Statement by ASCO President Clifford A. Hudis, MD, FACP, on ACS Report
“The American Cancer Society [recently] issued a report showing a 20% decline in cancer death rates between 1991 and 2010, and estimating that 1.3 million deaths have been averted as a result of the decline. “This is tremendous progress and a direct result of our nation’s commitment to cancer...
ASCO Statement on Annual Report to the Nation on the Status of Cancer
Clifford A. Hudis, MD, FACP, President of ASCO, commented recently on the Annual Report to the Nation on the Status of Cancer, co-authored by the National Cancer Institute, the American Cancer Society, the Centers for Disease Control and Prevention, and the North American Association of Central...
ASCO Celebrates 50 Years of Advancing Progress Against Cancer
Fifty years ago, cancer was viewed as a monolithic and largely untreatable disease, with only a handful of hard-to-tolerate and mostly ineffective therapies available. Stigma and silence left many patients with cancer with little support or information. Determined to change this, a group of seven...
50th Anniversary of the First U.S. Surgeon General’s Report on Smoking and Health
“When the first Surgeon General’s Report was released in 1964, more than half of American men and over a third of women smoked and lung cancer had gone from an obscure disease to a leading cause of death. In issuing this pioneering report summarizing the known health risks of smoking, our nation’s...
Nearly 40 Practices Receive QOPI® Recertification for High-Quality Cancer Care
Nearly 40 practices have achieved certification through the Quality Oncology Practice Initiative (QOPI®) Certification Program (QCP™) for a second 3-year term. The QOPI Certification Program began certifying practices in 2010 and is now seeing the first wave of practices applying for a second term. ...
ASCO President Issues Statement on Major Decline in Lung Cancer
Editor’s note: The Centers for Disease Control and Prevention (CDC) recently issued a report on lung cancer incidence trends in the United States.1 According to the report, incidence rates for lung cancer have decreased between 2005 and 2009, the period evaluated. Lung cancer incidence has...
Perspective on the Politics of Tobacco
The tobacco industry has always been a major player in congressional races, especially in Southern tobacco-growing states. Moreover, the industry is notoriously bipartisan in their political donations, and members of both parties have returned the favor by voting for tobacco interests. “The 2014...
The Surgeon General’s Report on Tobacco Turns 50: Much Success, Much Work Ahead
On January 11, 2014, the nation commemorated the 50th anniversary of a document that transformed our public health landscape and has saved millions of lives: Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service. This groundbreaking report, which...
ASCO Applauds CVS Caremark’s Move to Stop Selling Tobacco
CVS Caremark recently announced that it will stop selling cigarettes and other tobacco products at its more than 7,600 CVS/pharmacy stores across the United States by October 1, 2014, making CVS/pharmacy the first national pharmacy chain to take this step in support of the health and well-being of...
President Obama’s FY 2015 Budget Proposal
[On March 4, 2014], President Obama released his proposed budget for fiscal year 2015. Among several cost-cutting measures designed to preserve Medicare solvency is a proposal to reduce reimbursement for life-sustaining cancer drugs. Currently, reimbursement to physicians for “Part B” drugs is...
ASCO Holds Leadership Summit to Address Value in Cancer Care, Cost of Cancer Drugs and Technologies
ASCO convened a leadership summit in late January with pharmaceutical representatives, insurance payers, patient advocates, and physicians to initiate a dialogue on the challenge of defining value in cancer care. This meeting was held amid growing concerns about the sustainability of continued...
Who Pays for Noncompliance? The Hidden Costs of Our Current System
The development of novel targeted therapies that capitalize on our growing understanding of the molecular underpinnings and vulnerabilities of specific malignancies has to rank among the most important advances we have seen in the 50 years since the American Society of Clinical Oncology was...
Greatly Frustrated by Congressional Failure to Act on Sustainable Growth Rate
The American Society of Clinical Oncology (ASCO) is deeply frustrated by the failure of Congress to permanently repeal the flawed sustainable growth rate (SGR) formula used to set Medicare physician payments and passage of the 17th patch to the system. ASCO and the entire physician community worked ...
ASCO Releases Its First-Ever Report on the State of Cancer Care in America
On March 11, ASCO released its first-ever comprehensive assessment of the daunting challenges facing America’s ability to continue to deliver high-quality care to all patients with cancer. ASCO President Clifford A. Hudis, MD, FACP, introduced the assessment at a Congressional news briefing in...
ASCO Cofounder Jane Cooke Wright, MD, Defied Racial/Gender Barriers and Helped Usher in the Modern Age of Chemotherapy
When Jane Cooke Wright, MD, met with six other oncologists at the Edgewater Beach Hotel in Chicago on April 9, 1964, to discuss the creation of American Society of Clinical Oncology, the first medical society dedicated to bringing patient-oriented issues to clinical oncology, the Civil Rights Act...
ASCO Launches New Resources for Providers and Patients to Address Link Between Obesity and Cancer
As the obesity epidemic takes its toll on the nation’s health, ASCO is making strides to address this growing concern as it relates to cancer. ASCO has developed a suite of educational resources designed to help oncology providers educate their patients about the negative effects of obesity on...
Project Data Sphere: Megadata in the Cloud Could Speed Clinical Trials Here on Earth
Project Data Sphere, which launched on April 8, is a “giant digital laboratory, an enormous library containing data about tens of thousands of patients and hundreds of clinical trials, all of which will be in the public domain,” said Martin J. Murphy, Jr, DMedSc, PhD, FASCO, Chief Executive Officer ...
Reflecting on the Past Year and Looking Ahead to the Next
On assuming the Presidency of ASCO a year ago, I recognized that one of our greatest challenges as a professional society is helping the American public understand the value of cancer research, especially now, when scientific advances are accelerating but resources are contracting. This is partly...
ASCO Through the Years: Past Presidents
This year ASCO celebrates it's 50th Anniversary. Here is a list of past ASCO Presidents over these 50 years: 2014-2015: Peter P. Yu, MD 2013-2014: Clifford A. Hudis, MD 2012-2013: Sandra M. Swain, MD, FACP 2011-2012: Michael P. Link, MD 2010-2011: George W. Sledge, Jr, MD 2009-2010: Douglas W....
Congress Celebrates 50 Years of ASCO: Special Order on House Floor Honors Society’s Mid-Century Anniversary
The U.S. House of Representatives recently held a Special Order in honor of the American Society of Clinical Oncology (ASCO) as it celebrates its 50th anniversary. During the event on the House floor, Members of Congress highlighted critical advancements in cancer care over the past 50 years and...
Speaking Up Against High Cancer Drug Prices
Physicians have a duty to speak up against high cancer drug prices,” Hagop M. Kantarjian, MD, resolutely stated in an interview with The ASCO Post. “We should speak up because high drug prices are harming patients.” A leader in the effort to drive down the cost of drugs needed to treat patients...
ASCO Immediate Past President Hudis Urges Congress to Invest in Medical Research
In April, ASCO Immediate Past President Clifford A. Hudis, MD, FACP, urged Congress to recognize the need for further investment in medical research to protect this valuable infrastructure in testimony submitted to the U.S. Senate Committee on Appropriations. The testimony provided examples of how...
ASCO Takes Aim at the Link Between Obesity and Cancer
ASCO is stepping up its efforts to address the link between obesity and cancer—both as a leading cause of cancer and as a complicating factor for treatment. In recent years, research has demonstrated that a growing number of cancers are linked to obesity, and public health researchers predict that...
Expert Point of View: Clifford A. Hudis, MD, FACP
“To our surprise, obesity had a negative prognostic effect on premenopausal patients with breast cancer but not on those who were postmenopausal. We need to consider these findings in the context of results from other data sources that suggest that obesity remains a negative prognostic feature in...
Expert Point of View: Peter P. Yu, MD
Discussing the study on immediate vs deferred androgen deprivation therapy in the setting of prostate cancer with prostate-specific antigen (PSA)-only relapse, ASCO President Peter P. Yu, MD, noted that more than 60,000 men each year will face the dilemma of when to start androgen deprivation...
‘Unprecedented’ Survival Benefit in Prostate Cancer With Addition of Docetaxel to Hormone Therapy
Adding docetaxel to standard androgen ablation therapy (ie, testosterone suppression) extended survival by more than 1 year in men with newly diagnosed metastatic hormone-sensitive prostate cancer in the phase III E3805 trial, funded by the National Institutes of Health. As reported at the ASCO...
Videos Tell Stories of 50 Years of Progress Against Cancer
Nearly 3 years ago, ASCO launched CancerProgress.Net to mark the 40th anniversary of the signing of the U.S. National Cancer Act, which led to major new investments in cancer research and significant increases in cancer survival. The site provides a dynamic and interactive history of progress...
Combined With Chemotherapy, Cetuximab and Bevacizumab Found Comparable for First-Line Metastatic Colorectal Cancer Treatment
Call it a draw: Cetuximab (Erbitux), an EGFR inhibitor, and bevacizumab (Avastin), a VEGF inhibitor, confer comparable benefits as first-line treatment with chemotherapy for metastatic colorectal cancer, according to the phase III Cancer and Leukemia Group B (CALGB)/Southwest Oncology Group (SWOG) ...
Exemestane/Ovarian Suppression Reduces Recurrence vs Tamoxifen/Ovarian Suppression in Premenopausal Breast Cancer
A joint analysis of two important phase III clinical trials—TEXT (Tamoxifen and Exemestane Trial) and SOFT (Suppression of Ovarian Function Trial)—showed that exemestane plus ovarian function suppression was superior to tamoxifen plus ovarian suppression in preventing recurrence in premenopausal...
Navigating Cancer in the Era of Personalized Medicine: Rev 2014 Explores Emerging Issues, Ideas for Action
Diagnosed with stage IV non–small cell lung cancer in 2011, Stephen Wright turned to patient support groups where he learned about the anaplastic lymphoma kinase (ALK) mutation and a new drug that targeted it, crizotinib (Xalkori). He asked—then insisted—that he be tested for the mutation. He found ...
Federally Funded Trials Praised—and Underfunded
All four studies presented at the 2014 ASCO Annual Meeting Plenary Session were at least partially funded by federal dollars, bringing long overdue attention to the value of federally supported cancer research. Perhaps because of this high visibility, ASCO leaders took to the soapbox to sound the...
Stakeholders Are Uniting Around Value in Cancer Care
Judging from its visibility at the 2014 ASCO Annual Meeting, the concept of “value” in cancer care has reached critical mass. “ASCO is leading this difficult discussion on value in cancer care. This had to happen,” said Clifford A. Hudis, MD, FACP, Immediate Past President of ASCO and Chief of the ...
Take-Home Messages From ASCO's Immediate Past President
The ASCO Post recently spoke with ASCO Immediate Past President Clifford A. Hudis, MD, FACP, about his term as ASCO President. Dr. Hudis discussed his thoughts on ASCO today and shared his perspective on a number of important issues in oncology, including value in cancer care, big data, and more....
Center for Medicare and Medicaid Services Approves QOPI® as Pathway for Federally Required Quality Reporting
The Centers for Medicare and Medicaid Services (CMS) has approved ASCO’s Quality Oncology Practice Initiative (QOPI®) as a pathway for oncologists to meet the agency’s quality reporting requirements. Starting in the fall of 2014, oncology practices registered with QOPI will have the opportunity to...
A World Free From the Fear of Cancer—Is It Possible?
By every definition, ASCO’s 50th Annual Meeting was a huge success. The halls were buzzing as nearly 35,000 attendees shared excitement about cancer research. This was a banner year for federally funded clinical trials—all four of the abstracts selected for ASCO’s Plenary Session were backed by...
